Nasopharyngeal carcinoma treatment paradigm after HK0501–a potential way forward  

作　　者：Sharon S Poh Joseph TS Wee 

机构地区：[1]Department of Radiation Oncology,National Cancer Centre Singapore,Singapore 169610,Singapore [2]Oncology Academic Clinical Program,Duke-NUS Medical School,Singapore 169857,Singapore

出　　处：《Cancer Communications》2022年第9期801-803,共3页癌症通讯（英文）

摘　　要：The Hong Kong Nasopharyngeal Carcinoma(NPC)Study Group 0501 trial(HK0501)is the first trial that directly compares induction(IC)versus adjuvant chemotherapy(AC)both given together with concurrent chemoradiation(CCRT)treatment,which long has been a contentious issue[1].Its most salient finding is that when adjusted for platinum doses and other significant factors,the timing of the chemotherapy sequence is not important.In the era where chemotherapy is administered at maximum tolerated doses(MTD),the induction strategy has the advantage because of better tolerability.On the other hand,with the realization that there may be more ways to skin a cat,adjuvant metronomic chemotherapy has gained traction at the 2021 American Society of Clinical Oncology(ASCO)meeting[2]and provides an alternative to the decades’old dogma of MTD.Metronomic chemotherapy works by exerting an anti-angiogenic effect[3-6]and also has immune effects like removing regulatory T cells(Tregs)[7]and myeloid-derived suppressor cells(MDSCs)from the tumour microenvironment[8]and causing dendritic cell maturation,which upregulates and primes the anti-tumor T cell immune response[9,10].Pediatricians are probably the first to successfully incorporate 2 years of maintenance metronomic chemotherapy in their childhood acute lymphoblastic leukaemia protocols[11]which now boast cure rates of over 90%[12].

关 键 词：doses NASOPHARYNGEAL CARCINOMA 

分 类 号：R739.63[医药卫生—肿瘤]